Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace

Bio-Rad launches blood screening controls in Europe

January 2023—Bio-Rad Laboratories has announced that Exact Diagnostics HBV, HCV, and HIV-1 screen controls are available in Europe. The controls are designed to monitor the performance of blood donor screening assays and are calibrated against the Third WHO International Standard for HBV (NIBSC code 10/264) and HIV-1 (10/152) and the Fourth WHO International Standard for HCV (06/102). The products are made of whole viruses in a citrate plasma matrix to ensure lot-to-lot reproducibility, have an 18-month shelf life from date of manufacture when stored at −20°C or below, and are stable for 24 hours when stored at 2° to 8°C.

Thermo Fisher launches TrueMark infectious disease panels

January 2023—Thermo Fisher Scientific launched its TrueMark Infectious Disease Research Panels. The analytically sensitive, duplexed TaqMan assays are performed on pre-spotted and dried-down plates that include microorganism‑specific pathogens, using real‑time PCR techniques, which enables rapid and accurate detection for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases. The predefined and customizable panel options allow researchers to choose from more than 90 different bacterial and viral strain assays to generate results within four hours of taking the samples. Testing can be done from nasopharyngeal swabs or nasopharyngeal aspirate; vaginal, genital, and lesion swabs; or urine samples.

QuidelOrtho, Runda form joint venture to develop assays

January 2023—QuidelOrtho will form a joint venture between Ortho Clinical Diagnostics Trading, a subsidiary of QuidelOrtho, and Shanghai Medconn Biotechnology, a subsidiary of Shanghai Runda Medical Technology, to develop and manufacture assays in China for QuidelOrtho’s Vitros platform. Following a successful assay pilot program, the companies expect to begin developing a broader set of assays early this year in parallel with building out the joint venture organization in the Shanghai and Beijing areas.

Thermo Fisher liquid biopsy assays

February 2023—Thermo Fisher Scientific has introduced more than 50 Absolute Q liquid biopsy assays for research use. The wet lab verified liquid biopsy assays provide highly sensitive, specific nucleic acid quantification, enabling single nucleotide polymorphisms detection down to 0.1 percent variant allele frequency.

 

Roche announces collaboration with Pfizer

January 2023—Roche has entered into a collaboration with Pfizer to help patients access resources and locate information about COVID-19 testing, available treatment options, high-risk factors that increase the chance of progressing to severe COVID-19, and ways to seek timely care. People can learn why early testing is important at symptom onset, which health conditions increase the risk of progressing to severe COVID-19, and what treatment options are available on covid19knowmore.com, a Pfizer website. The Pilot COVID-19 At-Home Test, distributed in the U.S. by Roche and manufactured by SD Biosensor, will include a QR code that directs people to the website.

StatLab introduces staining platform, slides, TMA control

January 2023—StatLab has introduced the Quantum S2 automated special staining platform. The 36-slide capacity platform provides automation for more than 25 special stains, including GMS and Warthin-Starry silver stains, and uses MasterTech special stains, which produce bright, crisp, high-clarity stains, the company says.

IMV awards Werfen five ServiceTrak awards

February 2023—Werfen has received five 2022 IMV Service­Trak clinical laboratory awards in two categories. The company received best system performance and best service awards in the coagulation analyzers category, and awards for best customer satisfaction, best system performance, and best service in the blood gas category. This is the fourth consecutive year Werfen has been recognized in coagulation and the second time it has received all three awards in the blood gas category.

 

Qiagen, Helix partner to advance CDx for hereditary diseases

February 2023—Qiagen announced an exclusive strategic partnership with Helix to advance companion diagnostics for hereditary diseases. Under the agreement, Qiagen will be the exclusive marketing and contracting partner in the United States for Helix’s companion diagnostic services.

 

Vistapath introduces Sentinel platform

February 2023—Vistapath has introduced its flagship product, the Sentinel pathology processing platform. The platform uses machine vision combined with artificial intelligence to assess specimens and create a gross report in a few seconds. It consists of the Sentinel module, which measures 17 in. W × 12 in. D × 15 in. H, and the touchscreen, which measures 15 in. W × 8 in. D × 11 in. H.

 

FDA authorizes PerkinElmer Eonis kit for SMA screening in newborns

January 2023—PerkinElmer announced that the FDA has authorized the marketing of its Eonis SCID-SMA assay kit for in vitro diagnostic use by certified laboratories for the detection of spinal muscular atrophy and severe combined immunodeficiency in newborns. This is the first FDA-authorized assay for SMA screening in newborns in the United States, the company says, and is part of the company’s Eonis platform. The Eonis platform is a robust, flexible system that uses real-time PCR technology to screen for SMA and SCID using a single dried blood spot sample.

MARKETPLACE

TRENDING